|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
PPAR
Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein
Department of Internal Medicine and Molecular Science (B5), Graduate School of Medicine, Osaka University, Osaka, Japan
Insulin resistance and its dreaded consequence, type 2 diabetes, are major causes of atherosclerosis. Adiponectin is an adipose-specific plasma protein that possesses anti-atherogenic properties, such as the suppression of adhesion molecule expression in vascular endothelial cells and cytokine production from macrophages. Plasma adiponectin concentrations are decreased in obese and type 2 diabetic subjects with insulin resistance. A regimen that normalizes or increases the plasma adiponectin might prevent atherosclerosis in patients with insulin resistance. In this study, we demonstrate the inducing effects of thiazolidinediones (TZDs), which are synthetic PPAR
ligands, on the expression and secretion of adiponectin in humans and rodents in vivo and in vitro. The administration of TZDs significantly increased the plasma adiponectin concentrations in insulin resistant humans and rodents without affecting their body weight. Adiponectin mRNA expression was normalized or increased by TZDs in the adipose tissues of obese mice. In cultured 3T3-L1 adipocytes, TZD derivatives enhanced the mRNA expression and secretion of adiponectin in a dose- and time-dependent manner. Furthermore, these effects were mediated through the activation of the promoter by the TZDs. On the other hand, TNF-
, which is produced more in an insulin-resistant condition, dose-dependently reduced the expression of adiponectin in adipocytes by suppressing its promoter activity. TZDs restored this inhibitory effect by TNF-. TZDs might prevent atherosclerotic vascular disease in insulin-resistant patients by inducing the production of adiponectin through direct effect on its promoter and antagonizing the effect of TNF- on the adiponectin promoter.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. F. Bodary Links Between Adipose Tissue and Thrombosis in the Mouse Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2284 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liu, M. Grifman, J. Macdonald, P. Moller, F. Wong-Staal, and Q.-X. Li Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase J. Endocrinol., September 1, 2007; 194(3): 569 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Itoh, T. Suganami, N. Satoh, K. Tanimoto-Koyama, X. Yuan, M. Tanaka, H. Kawano, T. Yano, S. Aoe, M. Takeya, et al. Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1918 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Yuan, X. Chen, Q. Ma, J. Qiao, R. Li, X. Li, S. Li, J. Tang, L. Zhou, H. Song, et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes J. Endocrinol., August 1, 2007; 194(2): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katagiri, T. Yamada, and Y. Oka Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals Circ. Res., July 6, 2007; 101(1): 27 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lo, L. E. Bernstein, B. Canavan, M. Torriani, M. B. Jackson, R. S. Ahima, and S. K. Grinspoon Effects of TNF-{alpha} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E102 - E109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Chevillotte, M. Giralt, B. Miroux, D. Ricquier, and F. Villarroya Uncoupling Protein-2 Controls Adiponectin Gene Expression in Adipose Tissue Through the Modulation of Reactive Oxygen Species Production Diabetes, April 1, 2007; 56(4): 1042 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Cho, P. J. Park, H. J. Shin, Y.-K. Kim, D. W. Shin, E. S. Shin, H. H. Lee, B. G. Lee, J.-H. Baik, and T. R. Lee (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1166 - E1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, et al. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1213 - E1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Szmitko, H. Teoh, D. J. Stewart, and S. Verma Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1655 - H1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kikuchi, M. Yamada, T. Imakiire, T. Kushiyama, K. Higashi, N. Hyodo, K. Yamamoto, T. Oda, S. Suzuki, and S. Miura A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats J. Endocrinol., March 1, 2007; 192(3): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kanatani, I. Usui, K. Ishizuka, A. Bukhari, S. Fujisaka, M. Urakaze, T. Haruta, T. Kishimoto, T. Naka, and M. Kobayashi Effects of Pioglitazone on Suppressor of Cytokine Signaling 3 Expression: Potential Mechanisms for Its Effects on Insulin Sensitivity and Adiponectin Expression Diabetes, March 1, 2007; 56(3): 795 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hiuge, A. Tenenbaum, N. Maeda, M. Benderly, M. Kumada, E. Z. Fisman, D. Tanne, Z. Matas, T. Hibuse, K. Fujita, et al. Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Majuri, M Santaniemi, K Rautio, A Kunnari, J Vartiainen, A Ruokonen, Y A Kesaniemi, J S Tapanainen, O Ukkola, and L Morin-Papunen Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study Eur. J. Endocrinol., February 1, 2007; 156(2): 263 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Kraemer and V. D. Castracane Exercise and Humoral Mediators of Peripheral Energy Balance: Ghrelin and Adiponectin Experimental Biology and Medicine, February 1, 2007; 232(2): 184 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, F. B. Hu, and G. Curhan Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes Diabetes Care, February 1, 2007; 30(2): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sharma and B. Staels Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Potenza, F. L. Marasciulo, M. Tarquinio, M. J. Quon, and M. Montagnani Treatment of Spontaneously Hypertensive Rats With Rosiglitazone and/or Enalapril Restores Balance Between Vasodilator and Vasoconstrictor Actions of Insulin With Simultaneous Improvement in Hypertension and Insulin Resistance Diabetes, December 1, 2006; 55(12): 3594 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takano, Y. Kodama, Y. Kitta, T. Nakamura, J.-e. Obata, A. Mende, K.-i. Kawabata, Y. Saitoh, D. Fujioka, T. Kobayashi, et al. Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2641 - H2646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. ALEXANDRAKI, C. PIPERI, C. KALOFOUTIS, J. SINGH, A. ALAVERAS, and A. KALOFOUTIS Inflammatory Process in Type 2 Diabetes: The Role of Cytokines Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 89 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. TSATSANIS, V. ZACHARIOUDAKI, A. ANDROULIDAKI, E. DERMITZAKI, I. CHARALAMPOPOULOS, V. MINAS, A. GRAVANIS, and A. N MARGIORIS Peripheral Factors in the Metabolic Syndrome: The Pivotal Role of Adiponectin Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 185 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1100 - E1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ikeda, H. Maegawa, S. Ugi, Y. Tao, Y. Nishio, S. Tsukada, S. Maeda, and A. Kashiwagi Transcription Factor Activating Enhancer-binding Protein-2beta: A NEGATIVE REGULATOR OF ADIPONECTIN GENE EXPRESSION J. Biol. Chem., October 20, 2006; 281(42): 31245 - 31253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Otsuka, S. Sugiyama, S. Kojima, H. Maruyoshi, T. Funahashi, K. Matsui, T. Sakamoto, M. Yoshimura, K. Kimura, S. Umemura, et al. Plasma Adiponectin Levels Are Associated With Coronary Lesion Complexity in Men With Coronary Artery Disease J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1155 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bronsky, M. Karpisek, E. Bronska, M. Pechova, B. Jancikova, H. Kotolova, D. Stejskal, R. Prusa, and J. Nevoral Adiponectin, Adipocyte Fatty Acid Binding Protein, and Epidermal Fatty Acid Binding Protein: Proteins Newly Identified in Human Breast Milk Clin. Chem., September 1, 2006; 52(9): 1763 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kim, P. Pennisi, H. Zhao, S. Yakar, J. B. Kaufman, K. Iganaki, J. Shiloach, P. E. Scherer, M. J. Quon, and D. LeRoith MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E298 - E305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Kim, M Maachi, C Debard, E Loizon, K Clement, E Bruckert, B Hainque, J Capeau, H Vidal, and J P Bastard Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur. J. Endocrinol., July 1, 2006; 155(1): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakano, S. Tajima, A. Yoshimi, H. Akiyama, M. Tsushima, T. Tanioka, T. Negoro, M. Tomita, and T. Tobe A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin J. Lipid Res., July 1, 2006; 47(7): 1572 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Herder, H. Hauner, B. Haastert, K. Rohrig, W. Koenig, H. Kolb, S. Muller-Scholze, B. Thorand, R. Holle, and W. Rathmann Hypoadiponectinemia and Proinflammatory State: Two Sides of the Same Coin?: Results From the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4) Diabetes Care, July 1, 2006; 29(7): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I A Leclercq, C Sempoux, P Starkel, and Y Horsmans Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats Gut, July 1, 2006; 55(7): 1020 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. LeBrasseur, M. Kelly, T.-S. Tsao, S. R. Farmer, A. K. Saha, N. B. Ruderman, and E. Tomas Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E175 - E181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Punthakee, E. E. Delvin, J. O'Loughlin, G. Paradis, E. Levy, R. W. Platt, and M. Lambert Adiponectin, Adiposity, and Insulin Resistance in Children and Adolescents J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2119 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-Z. Yang, M.-J. Lee, H. Hu, J. Pray, H.-B. Wu, B. C. Hansen, A. R. Shuldiner, S. K. Fried, J. C. McLenithan, and D.-W. Gong Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1253 - E1261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms Circulation, April 18, 2006; 113(15): 1888 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Matsushita, H. Yatsuya, K. Tamakoshi, K. Wada, R. Otsuka, S. Takefuji, K. Sugiura, T. Kondo, T. Murohara, and H. Toyoshima Comparison of Circulating Adiponectin and Proinflammatory Markers Regarding Their Association With Metabolic Syndrome in Japanese Men Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 871 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kowalska, M. Straczkowski, A. Nikolajuk, A. Krukowska, I. Kinalska, and M. Gorska Plasma adiponectin concentration and tumor necrosis factor-{alpha} system activity in lean non-diabetic offspring of type 2 diabetic subjects Eur. J. Endocrinol., February 1, 2006; 154(2): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Bodary and D. T. Eitzman Adiponectin: Vascular Protection From the Fat? Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 235 - 236. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Schalkwijk, N. Chaturvedi, M. T. Schram, J. H. Fuller, C. D. A. Stehouwer, and the EURODIAB Prospective Complications Study Group Adiponectin Is Inversely Associated with Renal Function in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Abbasi, S.-A. Chang, J. W. Chu, T. P. Ciaraldi, C. Lamendola, T. McLaughlin, G. M. Reaven, and P. D. Reaven Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R139 - R144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gonzalez-Sanchez, M. J. Martinez-Calatrava, M. T. Martinez-Larrad, C. Zabena, C. Fernandez-Perez, M. Laakso, and M. Serrano-Rios Interaction of the -308G/A Promoter Polymorphism of the Tumor Necrosis Factor-{alpha} Gene with Single-Nucleotide Polymorphism 45 of the Adiponectin Gene: Effect on Serum Adiponectin Concentrations in a Spanish Population Clin. Chem., January 1, 2006; 52(1): 97 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, S. H. Han, and M. J. Quon Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stanley, K. Wynne, B. McGowan, and S. Bloom Hormonal Regulation of Food Intake Physiol Rev, October 1, 2005; 85(4): 1131 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suganami, J. Nishida, and Y. Ogawa A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes: Role of Free Fatty Acids and Tumor Necrosis Factor {alpha} Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2062 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W Peake, A. D Kriketos, L. V Campbell, Y. Shen, and J. A Charlesworth The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals Eur. J. Endocrinol., September 1, 2005; 153(3): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rothenbacher, H. Brenner, W. Marz, and W. Koenig Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers Eur. Heart J., August 2, 2005; 26(16): 1640 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Rossi, Y. B. Lombardo, J.-M. Lacorte, A. G. Chicco, C. Rouault, G. Slama, and S. W. Rizkalla Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R486 - R494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Di Gregorio, A. Yao-Borengasser, N. Rasouli, V. Varma, T. Lu, L. M. Miles, G. Ranganathan, C. A. Peterson, R. E. McGehee, and P. A. Kern Expression of CD68 and Macrophage Chemoattractant Protein-1 Genes in Human Adipose and Muscle Tissues: Association With Cytokine Expression, Insulin Resistance, and Reduction by Pioglitazone Diabetes, August 1, 2005; 54(8): 2305 - 2313. [Abstract] [Full Text] [PDF]
|
|